The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases

American Journal of Transplantation

Volumn 12, Issue 12, 2012, Pages 3296-3307

  Brouard, S ^a   Pallier, A ^a   Renaudin, K ^a,b   Foucher, Y ^b   Danger, R ^a   Devys, A ^c   Cesbron, A ^c   Guillot Guegen, C ^a   Ashton Chess, J ^a   Le Roux, S ^a,b   Harb, J ^a   Roussey, G ^a   Subra, J F ^d,e   Villemain, F ^d   Legendre, C ^f   Bemelman, F J ^g   Orlando, G ^h,t   Garnier, A ⁱ   Jambon, H ^j   Le Monies De Sagazan, H ^k   Braun, L ^l   Noel C ^s   Pillebout, E ^m   Moal, M C ⁿ   Cantarell, C ^o   Hoitsma, A ^p   Ranbant, M ^q   Testa, A ^r   Soulillou, J P ^a,b   Giral, M ^a,b   more..

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ D'ANGERS   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h SAN SALVATORE HOSPITAL   (Italy)

ⁱ HÔPITAL DES ENFANTS   (France)

^j GRENOBLE UNIVERSITY HOSPITAL   (France)

^k Hopital Victor Provo   (France)

^l UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ BREST UNIVERSITY HOSPITAL   (France)

^o HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^q HÔPITAL NECKER ENFANTS MALADES   (France)

^r ECHO Site du Confluent   (France)

^s LILLE UNIVERSITY HOSPITAL   (France)

^t WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Dysfunction; human; immunology; kidney; operational tolerance; transplantation

Indexed keywords

ALLOANTIBODY; AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; HLA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; STEROID;

CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HISTOLOGY; HLA TYPING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 84870566641     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04249.x     Document Type: Review

References (41)

1. Sola E, González-Molina M, Cabello M, et al,. Long-term improvement of deceased donor renal allograft survival since 1996: A single transplant center study. Transplantation 2012; 27: 714-720.
2. Soulillou J, Giral M,. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001; 72 (12 Suppl): S89-S93.
3. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP,. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403-406.
4. Dantal J, Hourmant M, Cantarovich D, et al,. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628.
5. Halloran P,. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
6. Morelon E, Stern M, Kreis H,. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000; 343: 225-226.
7. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
8. Chang SH CP, McDonald SP,. Effects of body mass index at transplant on outcomes of kidney transplantation. Transplantation 2007; 84: 981-987.
9. Vincenti FBG, Durrbach A, Friend P, et al,. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587-1596.
10. Danger R, Giral M, Soulillou JP, Brouard S,. Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation. Curr Opin Organ Transpl 2008; 13: 609-613.
11. Billingham RE, Brent L, Medawar PB,. Activity acquired tolerance of foreign cells. Nature 1953; 172: 603-606.
12. Lerut J, Sanchez-Fueyo A,. An appraisal of tolerance in liver transplantation. Am J Transpl 2006; 6: 1774-1780.
13. Martinez-Llordella M, Puig-Pey I, Orlando G, et al,. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transpl 2007; 7: 309-319.
14. Zoller KM, Cho SI, Cohen JJ, Harrington JT,. Cessation of immunosuppressive therapy after successful transplantation: A national survey. Kidney Int 1980; 18: 110-114.
15. Roussey-Kesler G, Giral M, Moreau A, et al,. Clinical operational tolerance after kidney transplantation. Am J Transpl 2006; 6: 736-746.
16. Sagoo P, Perucha E, Sawitzki B, et al,. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848-1861.
17. Newell KA, Asare A, Kirk AD, et al,. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836-1847.
18. Starzl TE, Murase N, Demetris AJ, et al,. Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation 2004; 77: 926-929.
19. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, et al,. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000; 106: 145-155.
20. Moraes-Vieira PM, Takenaka MC, Monteiro SM, et al,. Differential monocyte STAT6 activation and CD4(+)CD25(+)Foxp3(+) T cells in kidney operational tolerance transplanted individuals. Hum Immunol 2010; 71: 442-450.
21. Kawai T, Cosimi AB, Spitzer TR, et al,. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353-361.
22. Ballet C, Roussey-K, Aubin JT, et al,. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transpl 2006; 6: 2796-2801.
23. Baeten D, Louis S, Braud C, et al,. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 2006; 17: 294-304.
24. Louis S, Braudeau C, Giral M, et al,. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81: 398-407.
25. Pallier A, Hillion S, Danger R, et al,. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78: 503-513.
26. Sis B, Mengel MHM, Colvin RB, et al,. Banff'09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transpl 2010; 10: 464-471.
27. Solez K, Colvin RB, Racusen LC, et al,. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transpl 2008; 8: 753-760.
28. Wei Pan, Chappell R., A nonparametric estimator of survival functions for arbitrarily truncated and censored data. Lifetime Data Anal 1998; 4: 187-202.
29. Ballet C, Roussey-Kesler G, Aubin JT, et al,. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transpl 2006; 6: 2796-2801.
30. Londono MC, Danger R, Giral M, Soulillou JP, Sanchez-Fueyo A, Brouard S,. A need for biomarkers of operational tolerance in liver and kidney transplantation. Am J Transpl ant 2012; 12: 1370-1377.
31. Lozano JJ PA, Martinez-Llordella M, Danger R, et al,. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transpl 2011; 11: 1916-1926.
32. Merrill JP, Murray JE, Harrison JH, Guild WR,. Successful homotransplantation of the human kidney between identical twins. J Am Med Assoc 1956; 160: 277-282.
33. Adams AB, Williams MA, Jones TR, et al,. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887-1895.
34. Sachs DH,. Tolerance: Of mice and men. J Clin Invest 2003; 111: 1819-1821.
35. Ballet C, Renaudin K, Degauque N, et al,. Indirect CD4+ TH1 response, antidonor antibodies and diffuse C4d graft deposits in long-term recipients conditioned by donor antigens priming. Am J Transpl 2009; 9: 697-708.
36. Brouard S, Mansfield E, Braud C, et al., Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104: 15448-15453.
37. Gelson W, Hoare M, Vowler S, et al,. Features of immune senescence in liver transplant recipients with established grafts. Liver Transpl 2010; 16: 577-587.
38. Adeyi OA GA, Howe J, Marrari M, et al,. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol 2005; 14: 53-62.
39. Suthanthiran M,. Transplantation tolerance: Fooling mother nature. Proc Natl Acad Sci USA 1996; 93: 12072-12075.
40. Waldmann H, Cobbold S,. Regulating the immune response to transplants. A role for CD4+ regulatory cells Immunity 2001; 14: 399-406.
41. Giral M, Foucher Y, Karam G, et al,. Kidney and recipient weight incompatibility reduces long-term graft survival. J Am Soc Nephrol 2010; 21: 1022-1029.